Tarix Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Study of TXA127 Following Autologous Peripheral Blood Stem Cell ... ( CAMBRIDGE Mass. Feb. 23 2011 /- Tarix...)

HOME >> MEDICINE >> TECHNOLOGY

Tarix Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Study of TXA127 Following Autologous Peripheral Blood Stem Cell Transplant

Date:2/23/2011

CAMBRIDGE, Mass., Feb. 23, 2011 /PRNewswire/ -- Tarix Pharmaceuticals (www.tarixpharma.com) today announced enrollment of the first patient in a Phase 2 clinical study of TXA127, a pharmaceutical grade formulation of a naturally occurring peptide known to stimulate early hematopoietic precursor cells in the bone marrow. The study is currently enrolling patients undergoing autologous peripheral blood stem cell transplant to evaluate the safety and efficacy of TXA127 in accelerating engraftment following transplant.

Following a stem cell transplant, it can typically take several weeks for the stem cells to repopulate the patient's blood with platelets and other mature blood cells. During this time the patient is at increased risk of serious infection and bleeding. There are currently no drugs available that speed up the engraftment process.

"TXA127 has the potential to reduce the time it takes for blood cell counts to return to safe levels following stem cell transplant, which may accelerate the recovery process and reduce some of the health risks associated with stem cell transplant," stated Rick Franklin, CEO of Tarix Pharmaceuticals. "TXA127 is unique because it directly stimulates transplanted stem cells to replenish circulating platelets, white blood cells, and red blood cells."

TXA127 was granted Orphan Drug designation from the U.S. Food and Drug Administration (FDA) as a treatment to enhance engraftment in patients receiving a stem cell transplant. TXA127 has also received Orphan Drug designation for the treatment of Myelodysplastic Syndrome (MDS).

About the Phase 2 Program

The double-blind, placebo-controlled multi-center Phase 2 study will evaluate the safety and efficacy of TXA127 in the acceleration of engraftment following autologous peripheral blood stem cell transplant in patients with Hodgkin or non-Hodgkin lymphomas or multiple myeloma undergoing limited reinf
'/>"/>

SOURCE Tarix Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2
Related medicine technology :

1. Components of Extraneous Virus Detected in Rotarix Vaccine; No Known Safety Risk
2. Paul Capital Healthcare Purchases Additional Royalty Interest in GlaxoSmithKlines Rotarix(R)
3. New Data Published in The Lancet Show GSKs ROTARIX(R) Offers Protection Against the Most Common Circulating Rotavirus Types
4. New Data Show That GlaxoSmithKlines Rotarix(R) Could Be Given With Other Routine Infant Vaccines in the U.S.
5. Idenix Pharmaceuticals to Present at an Upcoming Investor Conference
6. Onyx Pharmaceuticals Reports Full Year and Fourth Quarter 2010 Financial Results
7. Avanir Pharmaceuticals to Present at Three Conferences in March
8. MAP Pharmaceuticals to Present at Upcoming Investor Conferences
9. Isis Pharmaceuticals Reports That Its Selective CRP Inhibitor Demonstrated Activity in a Phase 1 Study
10. Isis Pharmaceuticals to Present at the 2011 Citi Global Healthcare Conference
11. Inovio Pharmaceuticals to Present at Partnering and Scientific Conferences

Post Your Comments:

(Date:6/19/2013)... June 19, 2013 BioCision , a ... and handling in many areas of medical and ... patents by the U.S. Patent Office that apply ... to standardize sample handling to ensure the consistency ... common laboratory procedures. Patent number ...

(Date:6/19/2013)... , June 19, 2013 /PRNewswire/ -- Chindex International, ... American healthcare company providing services in ... Family Healthcare, a network of private hospitals and ... of its Beijing United Family Rehabilitation Hospital ("BJU ... of the United Family Healthcare ("UFH") network. On ...

(Date:6/19/2013)... , June 19, 2013 DST Health Solutions, ... services to health plans, integrated delivery systems, and health ... Medical Drug Management Service (MDMS) has jumped significantly. ... and automate the pricing of medical prescription drug claims, ... by automating their medical drug claims processes. As specialty ...

Breaking Medicine Technology:BioCision Announces Two New U.S. Patents for Thermo-Conductive Products that Standardize Sample Handling in Laboratory Research 2 Chindex International, Inc. Announces Opening of Beijing United Family Rehabilitation Hospital 2 Chindex International, Inc. Announces Opening of Beijing United Family Rehabilitation Hospital 3 Chindex International, Inc. Announces Opening of Beijing United Family Rehabilitation Hospital 4 Chindex International, Inc. Announces Opening of Beijing United Family Rehabilitation Hospital 5 Demand For DST's Medical Drug Management Service On The Rise As Health Plan Costs Increase 2 Demand For DST's Medical Drug Management Service On The Rise As Health Plan Costs Increase 3

[0] BioCision Announces Two New U.S. Patents for Thermo-Conductive Products that Standardize Sample Handling in Laboratory Research [0] Chindex International, Inc. Announces Opening of Beijing United Family Rehabilitation Hospital [0] Demand For DST's Medical Drug Management Service On The Rise As Health Plan Costs Increase

... NEW YORK, May 24, 2011 Reportlinker.com ... is available in its catalogue: ... Angiogenesis http://www.reportlinker.com/p0284984/Triple-Analysis-Lung-Cancer-Lymphoma-and-Angiogenesis.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ... on cancer drug development strategies in both ...

... YORK, May 24, 2011 Reportlinker.com announces ... available in its catalogue: ... http://www.reportlinker.com/p0284621/Triple-Analysis-Leukemia-Lymphoma-and-Peptides.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ... development strategies in both Leukemia and Lymphoma ...

Reportlinker Adds Triple Analysis: Lung Cancer, Lymphoma and Angiogenesis Reportlinker Adds Triple Analysis: Leukemia, Lymphoma and Peptides

(Date:6/19/2013)... (PRWEB) June 19, 2013 ... of neurologists, neurosurgeons, psychiatrists and urologists with specialists ... The team works with patients and their family ... overall quality of life. Patients also have the ... trials and research. , “Movement disorders can be ...

(Date:6/19/2013)... YOKOHAMA, Japan Leading Japanese pharmaceutical companies, along ... Melinda Gates Foundation, pledged their commitment to bolster ... Health Innovative Technology Fund (GHIT Fund), at a ... the fifth Tokyo International Conference on African Development ... partners including the Ministry of Health, Labour ...

(Date:6/19/2013)... Moffitt Cancer Center and colleagues at Louisiana State University ... that require immediate therapy. It relies on understanding the ... is to better predict a prostate cancer,s aggressiveness to ... published in the online journal PLOS ONE ... accounts for 20 percent of all cancers and 9 ...

(Date:6/19/2013)... 19, 2013 Brightree LLC , ... software solutions for the post-acute care industry, has been ranked ... the Healthcare Informatics 100 (HCI 100) list. This ... the U.S. in terms of revenue during the last fiscal ... rate of 85% annually, and the company has built its ...

(Date:6/19/2013)... City, MO (PRWEB) June 19, 2013 Kansas City ... part of Main Street Day . A section of Main ... pedestrian traffic during the afternoon of the event. The Main ... host the event, which will help Kansas City join the ranks ... used Ciclovia as a tool to foster community vibrancy and active ...

Breaking Medicine News(10 mins):Health News:Abington Memorial Hospital’s Neurosciences Institute Opens Movement Disorders Center 2 Health News:GHIT Fund celebrates historic beginning of Japanese R&D initiative in global health 2 Health News:GHIT Fund celebrates historic beginning of Japanese R&D initiative in global health 3 Health News:Moffitt Cancer Center researchers identify genetic variants predicting aggressive prostate cancers 2 Health News:Brightree Debuts on List of Top 100 Healthcare Technology Companies 2 Health News:Brightree Debuts on List of Top 100 Healthcare Technology Companies 3 Health News:Main Street Corridor Development Corporation and BikeWalkKC Partner to Host Main Street Day and Kansas City’s First Ciclovia 2 Health News:Main Street Corridor Development Corporation and BikeWalkKC Partner to Host Main Street Day and Kansas City’s First Ciclovia 3

[0] Abington Memorial Hospital’s Neurosciences Institute Opens Movement Disorders Center [0] GHIT Fund celebrates historic beginning of Japanese R&D initiative in global health [0] Moffitt Cancer Center researchers identify genetic variants predicting aggressive prostate cancers [0] Brightree Debuts on List of Top 100 Healthcare Technology Companies [0] Main Street Corridor Development Corporation and BikeWalkKC Partner to Host Main Street Day and Kansas City’s First Ciclovia

... access to medical product company,s industry-leading, non-invasive temperature therapy ... ... Tenn., May 29 Adroit Medical Systems, Inc.,today announced its award ... agreement centers on Adroit,s leading,Soft-Temp(R) hypo-hyperthermia blankets, localized heat therapy and ...

... Participating in Outdoor Activities, OFF!(R) Finds ... Uninterrupted, and Your ... sure do know how to make,the most out of their ... their families plan to attend a barbeque,(73 percent), watch fireworks ...

... ... Treatments, LAS ... and marketer of laser, light, and radiofrequency based,aesthetic devices, announced today ... platform for multiple aesthetic laser and,light treatments. The Harmony(XL) can be ...

... May 29 Darwin (NYSE: DR ),is ... product-centric underwriting,divisions, the health care division and the ... ), Under the leadership of senior ... newly created health care division combines all,of Darwin,s ...

... and complex condition that impacts about 15% of the ... known about the mechanisms behind the psychiatric disorder. ... parallels between depressive symptoms and the symptoms of certain ... in Molecular Psychiatry, researchers from University of Miami found ...

... to Cover ... Lost Income, NEW YORK, ... that U.S. employees are just,as concerned about the possibility of losing their ... to a recent survey,from Berkshire Life Insurance Company of America (Berkshire), a,wholly-owned ...

Adroit Medical Systems Awarded Premier Supplier Contract for Temperature Therapy Systems Keep Your Cool and Sanity This Summer!Alma Lasers Announces FDA Clearance of the Harmony(XL) Multi-Application System at THE Aesthetic Show 2008 Darwin Announces Creation of New Health Care and Errors and Omissions Divisions Inflammation, depression and antidepressant response: Common mechanisms Guardian Survey: Fear of Losing Income Due to the Economy Equals Fear of Losing Income Due to Disability

Colloidal Gold Conjugated, Goat anti-human IgG (H&L) - 50 OD...

Colloidal Gold Conjugated, Goat anti-human IgA (Alpha Chain) - 50 OD...

Polyester ribbons (3) impregnated with different OD values of conjugated Protein A...

Polyester ribbon impregnated with conjugated Protein A - .13 OD per sq. cm....

Medicine Products:

Goat Anti-Human IgG (H & L) Antibody, Colloidal Gold Conjugated, 50 OD Goat Anti-Human IgA, alpha chain Antibody, Colloidal Gold Conjugated, 50 OD Protein A Sample Pack - .13 OD ; .25 OD; .50 OD per sq. cm Protein A, Gold Ribbon - .13 OD per sq. cm.